Synapse - Neeta Pandit-Taskar

Results (47)

A phase 0 study to assess the biodistribution and pharmacokinetics of a radiolabeled antibody targeting human kallikrein 2 in participants with metastatic castration-resistant prostate cancer

Journal Article

Pandit-Taskar, N.; O'Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Ilovich, O.; Russell, M.; Nyima, T.; Divgi, C. R.; Yu, M.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: A pilot study

Journal Article

Lumish, M. A.; Maron, S. B.; Paroder, V.; Chou, J. F.; Capanu, M.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Lyashchenko, S. K.; more...
Journal of Nuclear Medicine (2023)

Fulltext@MSK | Save

Imaging HER2-positive metastatic esophagogastric cancer with (89)Zr-trastuzumab PET and (18)F-FDG PET

Meeting Abstract

Lumish, M. A.; Maron, S. B.; Paroder, V.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Janjigian, Y. Y.; Pandit-Taskar, N.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy

Meeting Abstract

Morris, M. J.; O' Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Russell, M.; Nyima, T.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy

Journal Article

Krebs, S.; O'Donoghue, J. A.; Biegel, E.; Beattie, B. J.; Reidy, D.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; Pandit-Taskar, N.
European Journal of Nuclear Medicine and Molecular Imaging (2020)

Fulltext@MSK | Save

Phase 0 study to assess [111In]-DOTA-h11B6 to target -human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer

Meeting Abstract

Morris, M. J.; O'Donoghue, J. A.; Chetty, D.; Russell, M.; Zulch, E.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

First-in-humans imaging with (89)Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: Preliminary pharmacokinetics, biodistribution, and lesion targeting

Journal Article

Pandit-Taskar, N.; Postow, M. A.; Hellmann, M. D.; Harding, J. J.; Barker, C. A.; O'Donoghue, J. A.; Ziolkowska, M.; Ruan, S.; Lyashchenko, S. K.; Tsai, F.; more...
Journal of Nuclear Medicine (2020)

Fulltext@MSK | Save

Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-satoreotide tetraxetan

Journal Article

Reidy-Lagunes, D.; Pandit-Taskar, N.; O'Donoghue, J. A.; Krebs, S.; Staton, K. D.; Lyashchenko, S. K.; Lewis, J. S.; Raj, N.; Gönen, M.; Lohrmann, C.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

(89)Zr-immuno-PET: Toward a noninvasive clinical tool to measure target engagement of therapeutic antibodies in vivo

Journal Article

Jauw, Y. W. S.; O'Donoghue, J. A.; Zijlstra, J. M.; Hoekstra, O. S.; Willemien Menke-van der Houven van Oordt, C.; Morschhauser, F.; Carrasquillo, J. A.; Zweegman, S.; Pandit-Taskar, N.; Lammertsma, A. A.; more...
Journal of Nuclear Medicine (2019)

Fulltext@MSK | Save

Retooling a blood-based biomarker: Phase I assessment of the high-affinity CA19-9 antibody HuMAB-5B1 for immuno-PET imaging of pancreatic cancer

Journal Article

Lohrmann, C.; O'Reilly, E. M.; O'Donoghue, J. A.; Pandit-Taskar, N.; Carrasquillo, J. A.; Lyashchenko, S. K.; Ruan, S.; Teng, R.; Scholz, W.; Maffuid, P. W.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save